TrialsgrambetaRCTs are beautiful

EMPHASIS-HF

2011

Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart Failure

In 2,737 patients with mild HFrEF (NYHA II, EF ≤ 35 %), eplerenone reduced cardiovascular death or heart-failure hospitalisation compared with placebo.

Result

Efficacy: CV death or HF hospitalisationHR 0.63

Below 1 favours eplerenone, above 1 favours placebo.

Event rates
Absolute difference
7.6 points

The absolute difference is derived from the event rates.

Original publication
Subtopic
MRA
Design
Double-blind RCT, stopped early
Relevance
Important: one of several pillars.
Source
Zannad F, et al. N Engl J Med. 2011;364(1):11-21.doi 10.1056/NEJMoa1009492

Discussion & critique

Extended MRA benefit from severe (RALES) to mild HF. Hyperkalaemia mandates monitoring; eplerenone avoids the gynaecomastia of spironolactone.

Discussed in podcasts